OBR News Hub

(AbbVie) Aug 29, 2019 - MERU, a Phase 3 placebo-controlled trial evaluating Rova-T as a first-line maintenance therapy for advanced small-cell lung cancer (SCLC), demonstrated no survival benefit for patients receiving Rova-T at the interim analysis. Independent Data Monitoring Committee recommended terminating the study due to lack of survival benefit.

AbbVie, a research based global biopharmaceutical company, today announced that MERU, a Phase 3 trial evaluating Rova-T as a first-line maintenance therapy for advanced small-cell lung cancer (SCLC), demonstrated no survival benefit at a pre-planned interim analysis for patients receiving Rova-T as compared with placebo.

Read Article (You will be redirected to AbbVie)
Today's Other Featured News Articles
View full issue >>
Yesterday's Featured News Articles
News Commentary
Editor Image
21 Sep, 2020 | by H. Jack West, MD
We can debate whether we're out far enough to call these patients cured, but...
View Comment
Editor Image
18 Sep, 2020 | by H. Jack West, MD
It's not really fair to compare survival on PACIFIC, which only enrolled...
View Comment